Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer Therapy
Patent grantee for vasopermeation enhancing agents
April 22nd, 2003
Peregrine Pharmaceuticals, Inc., (PPHM) announced the issuance of U.S. patent no. 6,524,823 covering liposomal conjugates that act to increase tumor blood vessel permeability. The patent, "Vasopermeability-enhancing conjugates," covers methods for selectively delivering liposomes to tumors which act to increase vascular permeability and expand blood volume at or in proximity to the tumor site. Researchers at the University of Southern California (USC), through a Peregrine-sponsored research collaboration, developed the vasopermeation enhancement agents (VEA) technology. This technology has been exclusively licensed to Peregrine from USC. ...
Source: Cancer Weekly (2003-04-22)
|
